MARKET

INSM

INSM

Insmed Inc
NASDAQ
27.29
-0.03
-0.11%
Opening 13:24 03/28 EDT
OPEN
27.22
PREV CLOSE
27.32
HIGH
27.55
LOW
27.01
VOLUME
411.33K
TURNOVER
0
52 WEEK HIGH
32.00
52 WEEK LOW
16.26
MARKET CAP
4.05B
P/E (TTM)
-5.1129
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at INSM last week (0318-0322)?
Weekly Report · 3d ago
Strong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed’s Brensocatib
TipRanks · 03/19 06:08
Weekly Report: what happened at INSM last week (0311-0315)?
Weekly Report · 03/18 09:14
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
TipRanks · 03/12 12:20
Weekly Report: what happened at INSM last week (0304-0308)?
Weekly Report · 03/11 09:14
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Zimmer Biomet Holdings (ZBH)
Insmed (INSM) and Zimmer Biomet Holdings (ZBH) have new ratings from analysts. Wells Fargo maintained a Buy rating on Insmed today and set a price target of $55.00. The company's shares closed at $27.99 today.
TipRanks · 03/07 12:30
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Insmed (INSM)
TipRanks · 03/05 12:40
Weekly Report: what happened at INSM last week (0226-0301)?
Weekly Report · 03/04 09:14
More
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Webull offers Insmed Inc stock information, including NASDAQ: INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INSM stock methods without spending real money on the virtual paper trading platform.